Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 2

Status

Unknown 1Completed 1

Sponsor Class

NIH 8INDUSTRY 7OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1

Conditions

Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 416Radiotherapy 276fludarabine 238Gemcitabine 211Cisplatin 203Nivolumab 184pembrolizumab 183Paclitaxel 176Carboplatin 168Magnetic Resonance Spectroscopy 166fludarabine phosphate 156Irinotecan 135Bevacizumab 133Cytarabine 128Specimen Handling 124Capecitabine 124Temozolomide 123Radiosurgery 118Docetaxel 116Biopsy 116Ipilimumab 113Dexamethasone 113Radiation 111Oxaliplatin 110Fluorouracil 110Rituximab 108Etoposide 108Filgrastim 99Lenalidomide 98Everolimus 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × OTHER × MK 2206 × Clear all
NCT01235897 2014-04-17

MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies

University of California, San Francisco

Phase 1 Completed
17 enrolled 7 charts
Tumor-Agnostic

Neoplasms

NCT01147211 2013-05-03

Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC)

National Taiwan University Hospital

Phase 1 Unknown
21 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡